FDA Approves ANDA216272 for Norepinephrine Bitartrate by Nephron
The FDA has approved ANDA216272, a generic formulation of Norepinephrine Bitartrate, submitted by Nephron.
Asset / Drug
Drug and asset intelligence for Nephron with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.